Nitric	O
oxide	O
synthase	O
inhibition	O
results	O
in	O
synergistic	O
anti	O
-	O
tumour	B-Cancer
activity	O
with	O
melphalan	O
and	O
tumour	O
necrosis	O
factor	O
alpha	O
-	O
based	O
isolated	O
limb	B-Organism_subdivision
perfusions	O
.	O

Nitric	O
oxide	O
(	O
NO	O
)	O
is	O
an	O
important	O
molecule	O
in	O
regulating	O
tumour	B-Cancer
blood	B-Organism_substance
flow	O
and	O
stimulating	O
tumour	B-Cancer
angiogenesis	O
.	O

Inhibition	O
of	O
NO	O
synthase	O
by	O
L	O
-	O
NAME	O
might	O
induce	O
an	O
anti	O
-	O
tumour	B-Cancer
effect	O
by	O
limiting	O
nutrients	O
and	O
oxygen	O
to	O
reach	O
tumour	B-Tissue
tissue	I-Tissue
or	O
affecting	O
vascular	B-Multi-tissue_structure
growth	O
.	O

The	O
anti	O
-	O
tumour	B-Cancer
effect	O
of	O
L	O
-	O
NAME	O
after	O
systemic	O
administration	O
was	O
studied	O
in	O
a	O
renal	B-Cancer
subcapsular	I-Cancer
CC531	I-Cancer
adenocarcinoma	I-Cancer
model	O
in	O
rats	O
.	O

Moreover	O
,	O
regional	O
administration	O
of	O
L	O
-	O
NAME	O
,	O
in	O
combination	O
with	O
TNF	O
and	O
melphalan	O
,	O
was	O
studied	O
in	O
an	O
isolated	O
limb	B-Organism_subdivision
perfusion	O
(	O
ILP	O
)	O
model	O
using	O
BN175	B-Cancer
soft	I-Cancer
-	I-Cancer
tissue	I-Cancer
sarcomas	I-Cancer
.	O

Systemic	O
treatment	O
with	O
L	O
-	O
NAME	O
inhibited	O
growth	O
of	O
adenocarcinoma	B-Cancer
significantly	O
but	O
was	O
accompanied	O
by	O
impaired	O
renal	B-Organ
function	O
.	O

In	O
ILP	O
,	O
reduced	O
tumour	B-Cancer
growth	O
was	O
observed	O
when	O
L	O
-	O
NAME	O
was	O
used	O
alone	O
.	O

In	O
combination	O
with	O
TNF	O
or	O
melphalan	O
,	O
L	O
-	O
NAME	O
increased	O
response	O
rates	O
significantly	O
compared	O
to	O
perfusions	O
without	O
L	O
-	O
NAME	O
(	O
0	O
-	O
64	O
%	O
and	O
0	O
-	O
63	O
%	O
respectively	O
)	O
.	O

An	O
additional	O
anti	O
-	O
tumour	B-Cancer
effect	O
was	O
demonstrated	O
when	O
L	O
-	O
NAME	O
was	O
added	O
to	O
the	O
synergistic	O
combination	O
of	O
melphalan	O
and	O
TNF	O
(	O
responses	O
increased	O
from	O
70	O
to	O
100	O
%	O
)	O
.	O

Inhibition	O
of	O
NO	O
synthase	O
reduces	O
tumour	B-Cancer
growth	O
both	O
after	O
systemic	O
and	O
regional	O
(	O
ILP	O
)	O
treatment	O
.	O

A	O
synergistic	O
anti	O
-	O
tumour	B-Cancer
effect	O
of	O
L	O
-	O
NAME	O
is	O
observed	O
in	O
combination	O
with	O
melphalan	O
and	O
/	O
or	O
TNF	O
using	O
ILP	O
.	O

These	O
results	O
indicate	O
a	O
possible	O
role	O
of	O
L	O
-	O
NAME	O
for	O
the	O
treatment	O
of	O
solid	O
tumours	B-Cancer
in	O
a	O
systemic	O
or	O
regional	O
setting	O
.	O

